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Active Bacterial Core Surveillance (ABCs) Report 
Emerging Infections Program Network 
Methicillin-Resistant Staphylococcus aureus, 2012
ABCs Areas 
Cal i fornia (3 county San Francisco Bay area); Colorado (5 county Denver area); Connecticut; Georgia (8 county Atlanta area); Maryland (Bal timore 
Ci ty and County); Minnesota (2 metro Twin Ci ty counties); New York (1 Rochester county); Oregon (3 county Portland area); Tennessee (1 Nashville 
county).   
 
ABCs Population 
The survei l lance areas  represent 19,635,461 persons  
Source: National  Center for Health Statis tics  bridged -race vintage 2012 postcensal  fi le.   
 
ABCs Case Definition 
Invasive methicillin-resistant Staphylococcus aureus (MRSA) disease:  isolation of MRSA from a normally s terile site in a resident of the surveillance 
area  in 2012.  Cases of disease are classified into one of three epidemiologic classifications.  A case is classified as hospital-onset (HO) i f the MRSA 
culture was obtained on or after the fourth ca lendar day of hospita l i zation, where admiss ion is  hospita l  day 1;  as  healthcar e-associated 
community-onset (HACO) i f the culture was obtained in an outpatient setting  or before the fourth calendar day of hospitalization and had one of 
more of the following: 1) a  history of hospitalization, surgery, dialysis, or res idence in a  long term care faci l i ty in the p revious  year, or 2) the 
presence of a  central vascular catheter (CVC) within 2 days prior to MRSA culture; and as community-associated (CA) i f none of the previous ly 
mentioned cri teria  are met. 
 
ABCs Methodology 
ABCs  personnel routinely contacted a ll microbiology laboratories serving healthcare facilities in their area  to identi fy cases . Standardized case  
report forms that include information on demographic characteristics, cl inical syndrome, and outcome of illness were complete d for each identified 
case.  Convenience samples of isolates were collected and sent to CDC for routine testing, including antimicrobia l  susceptibi l i ty testing, toxin 
testing, SCCmec typing, and spa typing. Pulsed field gel electrophoresis (PFGE) of all isolates was discontinued in 2008; up unti l  2012, PFGE  was  
inferred based on a  va lidated algorithm (http://www.cdc.gov/HAI/settings/lab/inferred-PFGE-algorithm.html).  Starting in 2012, spa  typing was  
added to the routine laboratory testing.  Pulsed field type is currently inferred based on spa type, inferred MLST clonal  complex and molecular 
characteristics of the isolates (http://www.cdc.gov/HAI/settings/lab/CCalgori thm.html) .  In 2012, i solates  were only col lected in five s i tes  
(Ca l ifornia, Georgia, Minnesota, New York, and Tennessee). Regular laboratory audits were performed to ensure completeness of case detection. 
 
Rates of invasive MRSA disease among all patients were calculated using population estimates for 2012.  Cases with unknown race were ass igned 
race based on distribution of known race and gender by EIP site.  Confidence intervals for nationally estimated incidence rates  of disease and 
morta l i ty were ca lculated based on the gamma dis tribution (Stat Med, 1997 16:791-801).   
 
Rates of invasive MRSA disease among patients who were undergoing chronic dialysis treatment were ca lcul ated us ing the December 31, 2011 




















Reported Race among 4582 Cases 
Race                               No.    (Rate) 
a
          
White 2869 (20.9) 
Black 1554   (40.9) 
Other 159 (7.6) 
 
Unknown race (n=391) distributed amongst known 
a Cases per 100,000 population for ABCs areas (crude rates) 
Cases, Deaths & Inferred PFGE  type by Epidemiological Classification 
MRSA 
Class 
No. (Rate)  
Cases b 
No. (Rate)  
Deaths c 
Inferred PFGE Type (%) 
Tot N USA100 USA300 
USA500/ 
Iberian 
CA 937 (4.8) 85 (0.4) 145 30 (20.7) 100 (69.0) 5 (3.5) 
HCA 
a
 3565 (18.1) 475 (2.4) 535 267 (49.9) 150 (28.0) 69 (12.9) 
HO 788 (4.0) 120 (0.6) 110 52 (47.3) 38 (34.6) 11 (2.7) 
HACO 2777 (14.1) 355 (1.8) 425 215 (50.6) 112 (26.4) 58 (13.7) 
a HCA: Healthcare-associated invasive MRSA infection; sum of patients that are classified 
as  either the HO or HACO classes 
b n= 80 epidemiologic category unknown 
c n=6;  epidemiologic category unknown 
 
Reported Cases on Chronic Dialysis (n=869) 
Dialysis and Access Type No.   (%) 




      Peri toneal 29 (3.3) 
      Hemodialysis 832 (95.7) 
AV Fis tula/Graft 361 (43.4) 
CVC 440 (52.9) 
Unknown 31 (3.7) 







































 No. (%) No. (%) No. (%) 
Bloodstream Infection b 
with other syndrome 
   
477 (50.9) 1368 (49.3) 251 (31.9) 
with no other syndrome 170 (18.1) 850 (30.6) 262 (33.2) 
Pneumonia 124 (13.2) 318 (11.5) 123 (15.6) 
Lower Respiratory Infection c 34 (3.6) 87 (3.1) 45 (5.7) 
Osteomyelitis 150 (16.0) 421 (15.2) 145 (18.4) 
Endocarditis 67 (7.2) 135 (4.9) 25 (3.2) 
Cel lulitis 200 (21.3) 216 (7.8) 68 (8.6) 
Wounds     
Surgical d 19 (2.0) 191 (6.9) 51 (6.5) 
Decubitus/Pressure Ulcers 16 (1.7) 69 (2.5) 24 (3.1) 
Skin Abscesses e 109 (11.6) 94 (3.4) 26 (3.3) 
Other Woundsf 25 (2.7) 99 (3.6) 19 (2.4) 
Traumatic 13 (1.4) 12 (0.4) 8 (1.0) 
a 
Some case patients had more than one syndrome. 
b 
Catheter site infection or AV fistula infection only are included in BSI with other syndrome. 
c 
Lower Respiratory Infection is defined as:  a patient with pneumonia documented in their discharge summary, who has a 
positive MRSA non-sterile respiratory specimen with accompanying chest radiology results documenting any of the 
following: bronchopneumonia/pneumonia, air space density/opacity, new or changed infiltrates. 
d
 Combines deep tissue/organ infection and infection of a surgical wound, post operatively. 
e 
Category includes skin abscess, necrotizing fasciitis, gangrene.  Number of cases considered as skin abscess was expanded 
for the 2012 annual summary. 
f
Category includes non-traumatic and other chronic wound infections. 
 
National Estimates and Adjusted Incidence Rates of Invasive MRSA Infections 
Epidemiologic 
Category 
Estimated Cases of Infection 
Non-Dia lys is  Patients  Dia lys is  Patients  Tota l  
 Es timated 
No. 














CA 15,138 4.82 (3.69-6.42) NA NA 15,138 4.82 (3.69-6.42) 
HCA 44,771 14.29 (12.40-16.62) 14,041 3262.39 (2496.82-4247.12) 58,812 18.74 (15.81-22.42) 
      HO 11,493 3.67 (2.73-5.02) 1,408 327.24  (131.31-739.07) 12,901 4.11 (2.90-6.02) 
      HACO 33,278 10.62 (9.06-12.55) 12,633 2936.08 (2216.06-3876.65) 45,911 14.63 (12.09-17.85) 
Overa l l c 61,268 19.54 (17.24-22.31) 14,041 3263.31 (2496.12-4248.98) 75,309 23.99 (20.64-28.10) 
a
 National Estimates and Incidence (no. per 100,000 population per year) are adjusted for age,  race, gender and receipt of chr onic dialysis using 2012 US Census Data.  
b
 National Estimates and Incidence (no. per 100,000 dialysis patients per year) for dialysis patients are adjusted for age, race and gender using 201 1 USRDS point prevalence data.   
c 
80 cases could not be classified into an epidemiological category or category is unknown and therefore are counted in the overal l estimate only.   
d
 Starting in 2011, confidence intervals on national estimates were determined for each of the 72 age/race/gend er/dialysis specific strata and summarized for an overall national 


























Age Group  
Incidence of Invasive MRSA, by 
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National Metric for Healthy People 2020 and the Department of Health and Human Services Action Plan to Prevent Healthcare-Associated 
Infections 
ABCs Discussion 
Survei llance data from 2012 represent the eighth full year of performing population-based surveillance for invasive MRSA infections through the 
Emerging Infections Program/Active Bacterial Core Surveillance Activi ty.  
Overa l l, compared to the baseline incidence (2007-2008 ca lendar years) identified in the HHS Action Plan, there was a decrease of 30.80%.  
Citation 
1. Centers for Disease Control and Prevention. 2012. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Methicillin -
Resistant Staphylococcus aureus, 2012.   
Available via the Internet: http://www.cdc.gov/abcs/reports-findings/survreports/mrsa12.pdf 
For more information, visit our web sites:  http://www.cdc.gov/abcs/index.html, 
http://www.cdc.gov/mrsa
National Estimates and Adjusted Incidence Rates for Mortality among Cases 
Epidemiologic Class Estimated No. Mortality Rate 
(Confidence Interval) 
a
CA 1,444 0.46 (0.22-0.93) 
HCA 8,128 2.59 (1.74-3.88) 
HO 2,045 0.65 (0.31-1.35) 
HACO 6,083 1.94 (1.23-3.10) 
Overal l b 9,670 3.08 (2.15-4.48) 
a National Estimates and Mortality Rate (no. per 100,000 population per year) 
are adjusted for age, race, gender and receipt of chronic dialysis using 2012 US 
Census Data 
b 
80  cases could not be classified into an epidemiological category or category i s 
unknown and therefore are counted in the overall estimate only. 
Disease Rate  Estimate of Cases in United States. a
Baseline (07-08) 2012 % Change Baseline (07-08) 2012 Difference 
HCA  27.08 18.74 -30.80 82,000 59,000 23,000 
a  Disease Rate (no. per 100,000 population per year) and National Estimates are adjusted for age, race, 
gender and receipt of chronic dialysis  using 2011 US Census Data 
